Benzbromarone gout,treatment

This potent uricosuric agent is used in Europe. It is a potent and reversible inhibitor of the urate-anion exchcmger in the proximal tubule. As the micronized powder, it is effective in a single daily dose of 40-80 mg. It is effective in patients with renal insufficiency and may be useful clinically in patients who are either allergic or refractory to other drugs used for the treatment of gout. Preparations that combine allopurinol and benzbromarone lower serum uric acid levels more effectively than either drug alone, despite the fact that benzbromarone lowers plasma levels of oxypurinol, the active metabolite of allopurinol. 

Unlike benzbromarone 48, which was not marketed in the United States and had limited availability in Europe due to fatal liver toxicity, lesinurad sodium 49 (RDEA-594), discovered and developed by Ardea Biosciences, is a selective inhibitor of urate-anion transporter (URATl), a transporter in kidney cells that regulates uric acid excretion from the body. Lesinurad is currently in phase III clinical trials as a once-daily treatment for gout. AstraZeneca acquired Ardea Biosciences in April, 2012 due to this advanced drug candidate and two other drug compounds at the cost of 1.26 billion. It was expected that lesinurad would be filing for regulatory approval in the United States and Europe soon. 

TREATMENT OF GOUT AND HYPERURICAEMIA BY BENZBROMARONE ETHYL 2 (DIBROMO -3,5 HYDROXY - 4 BENZOYL) - 3 BENZOFURAN... 

Treatment of Gout and Hyperuricaemia by Benzbromarone, Ethyl 2 (Dibromo-3,5 Hydroxy-4... 

---